JP2007504212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504212A5 JP2007504212A5 JP2006525214A JP2006525214A JP2007504212A5 JP 2007504212 A5 JP2007504212 A5 JP 2007504212A5 JP 2006525214 A JP2006525214 A JP 2006525214A JP 2006525214 A JP2006525214 A JP 2006525214A JP 2007504212 A5 JP2007504212 A5 JP 2007504212A5
- Authority
- JP
- Japan
- Prior art keywords
- drug release
- hours
- pharmaceutical composition
- release
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims 27
- 239000003814 drug Substances 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 13
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 5
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 4
- 229960004909 aminosalicylic acid Drugs 0.000 claims 4
- 238000004090 dissolution Methods 0.000 claims 4
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 4
- 229960004963 mesalazine Drugs 0.000 claims 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 4
- 229960001860 salicylate Drugs 0.000 claims 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 4
- 229960004889 salicylic acid Drugs 0.000 claims 4
- KUNZMYAVFWDQKQ-UHFFFAOYSA-N 4-[(4-carboxy-3-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC=C1N=NC1=CC=C(C(O)=O)C(O)=C1 KUNZMYAVFWDQKQ-UHFFFAOYSA-N 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- ITHFNJCQUCSZHH-UHFFFAOYSA-N 4-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC=C1N=NC1=CC=C(O)C(C(O)=O)=C1 ITHFNJCQUCSZHH-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- QQBDLJCYGRGAKP-UHFFFAOYSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-UHFFFAOYSA-N 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49936503P | 2003-09-03 | 2003-09-03 | |
| US60/499,365 | 2003-09-03 | ||
| PCT/IB2004/003059 WO2005021009A2 (en) | 2003-09-03 | 2004-09-02 | Formulations and methods of treating inflammatory bowel disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007504212A JP2007504212A (ja) | 2007-03-01 |
| JP2007504212A5 true JP2007504212A5 (enExample) | 2007-10-18 |
| JP5108304B2 JP5108304B2 (ja) | 2012-12-26 |
Family
ID=34272809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525214A Expired - Fee Related JP5108304B2 (ja) | 2003-09-03 | 2004-09-02 | 炎症性腸疾患の治療用製剤及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7737133B2 (enExample) |
| EP (1) | EP1663253B1 (enExample) |
| JP (1) | JP5108304B2 (enExample) |
| AT (1) | ATE489956T1 (enExample) |
| AU (1) | AU2004267953A1 (enExample) |
| CA (1) | CA2535923A1 (enExample) |
| DE (1) | DE602004030353D1 (enExample) |
| ES (1) | ES2353761T3 (enExample) |
| IL (1) | IL173684A0 (enExample) |
| MX (1) | MXPA06002048A (enExample) |
| NO (1) | NO20061489L (enExample) |
| WO (1) | WO2005021009A2 (enExample) |
| ZA (1) | ZA200601356B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2112920B1 (en) | 2003-06-26 | 2018-07-25 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US7825106B2 (en) * | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
| US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
| EP2361620B1 (en) | 2004-02-06 | 2016-04-06 | PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST | Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome |
| JP5009152B2 (ja) * | 2004-05-28 | 2012-08-22 | サリックス ファーマシューティカルズ， インコーポレイテッド | 放射線誘発性腸炎の予防、処置、および回復 |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| US20090017110A1 (en) * | 2005-05-31 | 2009-01-15 | Capricorn Pharma Inc. | Modified release formulations of anti-irritability drugs |
| US20070015689A1 (en) * | 2005-06-23 | 2007-01-18 | Alza Corporation | Complexation of metal ions with polypeptides |
| NZ603744A (en) * | 2005-08-24 | 2014-06-27 | Salix Pharmaceuticals Inc | Balsalazide formulations and manufacture and use thereof |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| US7452872B2 (en) | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| US8679545B2 (en) * | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| WO2007112581A1 (en) | 2006-04-03 | 2007-10-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| EP2050439B1 (en) * | 2006-08-11 | 2016-11-23 | Asahi Kasei Kabushiki Kaisha | Process for production of spherical granule containing slightly water-soluble substance |
| WO2008027557A2 (en) * | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| WO2008043107A2 (en) * | 2006-10-06 | 2008-04-10 | Alba Therapeutics Corporation | Use of tight junction antagonists to treat inflammatory bowel disease |
| MX2009001711A (es) | 2006-11-17 | 2009-05-08 | Supernus Pharmaceuticals Inc | Formulaciones de liberacion sostenida de topiramato. |
| EP2363113B1 (en) * | 2006-12-04 | 2017-08-02 | Supernus Pharmaceuticals, Inc. | Enhanced immediate release formulations of topiramate |
| WO2008085484A2 (en) * | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
| GB2461822B (en) * | 2007-03-20 | 2011-09-21 | Isp Investments Inc | Meltable binder for melt granulation and/or pelletization |
| US20090036414A1 (en) * | 2007-08-02 | 2009-02-05 | Mutual Pharmaceutical Company, Inc. | Mesalamine Formulations |
| JP2011500553A (ja) * | 2007-10-10 | 2011-01-06 | ルピン・リミテッド | ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤 |
| US20090162434A1 (en) * | 2007-12-21 | 2009-06-25 | Disphar International Bv | Mesalazine tablet |
| US20120093939A1 (en) * | 2008-12-17 | 2012-04-19 | Altheus Therapeutics, Inc. | Oral formulations |
| CA3014688A1 (en) | 2008-12-19 | 2010-07-15 | Supernus Pharmaceuticals, Inc. | Use of molindone for the treatment of aggression, irritability, or impulsivity |
| US8748472B2 (en) | 2010-03-31 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Stabilized formulations of CNS compounds |
| US8597683B2 (en) * | 2010-11-30 | 2013-12-03 | Watson Pharmaceuticals, Inc. | Modified release tranexamic acid formulation |
| AU2013229990B2 (en) * | 2012-03-07 | 2017-07-06 | Santarus, Inc. | Controlled-release solid dosage forms of mesalamine |
| US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
| JP5897196B1 (ja) * | 2015-10-05 | 2016-03-30 | 大同化成工業株式会社 | 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法 |
| US20170119680A1 (en) | 2015-10-30 | 2017-05-04 | R.P. Scherer Technologies, Llc | Extended release film-coated capsules |
| CA3086767A1 (en) * | 2018-01-03 | 2019-07-11 | Ferring B.V. | Oral liquid pharmaceutical compositions of aminosalicylates |
| US12053447B2 (en) | 2019-06-25 | 2024-08-06 | NuBioPharma, LLC | Oral solution and powder to liquid compositions of balsalazide |
| CN112569915B (zh) * | 2020-12-27 | 2023-06-23 | 王晓玉 | 一种煤矿井水除铀吸附剂、及其制备方法和应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57500432A (enExample) * | 1980-03-20 | 1982-03-11 | ||
| SE8002322L (sv) * | 1980-03-26 | 1981-09-27 | Pharmacia Ab | Medel for behandling av inflammatoriska tarmsjukdomar |
| US4374932A (en) * | 1981-06-08 | 1983-02-22 | G. D. Searle & Co. | 5-ASA Drug delivery system |
| ZA825384B (en) * | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| SE8303399D0 (sv) * | 1983-06-15 | 1983-06-15 | Pharmacia Ab | Azo-bis-salicyl syra och salt derav, deras farmaceutiska beredning samt framstellning av syran |
| SE8303400D0 (sv) | 1983-06-15 | 1983-06-15 | Pharmacia Ab | Azo-bis-salicylsyra och salt derav samt deras farmaceutiska beredning och anvendning |
| US4693895A (en) * | 1984-10-26 | 1987-09-15 | Alza Corporation | Colon delivery system |
| US4705515A (en) * | 1984-10-26 | 1987-11-10 | Alza Corporation | Dosage form for administering drug of the colon |
| US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
| US4608048A (en) | 1984-12-06 | 1986-08-26 | Alza Corporation | Dispensing device with drug delivery patterns |
| US4904474A (en) * | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
| US5330998A (en) * | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| US5256675A (en) * | 1989-08-07 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same |
| IE68593B1 (en) * | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| IL98087A (en) * | 1990-05-04 | 1996-11-14 | Perio Prod Ltd | Preparation for dispensing drugs in the colon |
| SE9002339L (sv) | 1990-07-04 | 1992-01-05 | Kabi Pharmacia Ab | Terapeutisk komposition och foerfarande foer dess framstaellning |
| US5519014A (en) | 1990-10-22 | 1996-05-21 | Borody; Thomas J. | Treatment of non-inflammatory and non-infectious bowel disorders |
| FR2692484B1 (fr) | 1992-06-22 | 1995-06-30 | Gouchet Franck | Nouvelle forme galenique de 4-asa a liberation controlee. |
| WO1995016451A1 (fr) | 1992-06-22 | 1995-06-22 | Franck Arno Gouchet | Comprimes a liberation controlee de 4-asa |
| DE69425453T2 (de) * | 1993-04-23 | 2001-04-12 | Novartis Ag, Basel | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
| DK66493D0 (da) * | 1993-06-08 | 1993-06-08 | Ferring A S | Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling |
| JPH072650A (ja) * | 1993-06-18 | 1995-01-06 | Tanabe Seiyaku Co Ltd | 放出部位制御型製剤 |
| US5482718A (en) | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
| ATE357221T1 (de) * | 1994-04-22 | 2007-04-15 | Astellas Pharma Inc | Kolon-spezifisches arzneistofffreisetzungssystem |
| GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| JPH0840941A (ja) * | 1994-07-29 | 1996-02-13 | Kanegafuchi Chem Ind Co Ltd | 炎症性腸疾患治療製剤 |
| US5608048A (en) * | 1995-06-05 | 1997-03-04 | Bristol-Myers Squibb Company | d4 T polymorphic Form 1 process |
| US6004581A (en) * | 1995-12-21 | 1999-12-21 | Farmaceutisk Laboratorium Ferring A/S | Modified release oral pharmaceutical composition and method for the treatment of bowel diseases |
| US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| DE19732903A1 (de) * | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
| EP1101490B1 (en) | 1998-07-28 | 2005-04-13 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
| JP2000103732A (ja) * | 1998-07-28 | 2000-04-11 | Tanabe Seiyaku Co Ltd | 腸内適所放出型製剤 |
| KR100695562B1 (ko) | 1998-09-28 | 2007-03-15 | 워너-램버트 캄파니 엘엘씨 | Ｈｐｍｃ 캡슐을 이용한 장 및 결장에의 전달방법 |
| US6733789B1 (en) * | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
| DE59905248D1 (de) * | 1999-01-29 | 2003-05-28 | Disphar Int Bv | Pharmazeutische zusammensetzungen |
| ITMI991316A1 (it) | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | Composizioni farmaceutiche orali a rilascio modificato di mesalazina |
| DE10013029A1 (de) * | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Mehrschichtige Arzneiform für die Colonfreigabe |
| AU2001279064A1 (en) * | 2000-07-27 | 2002-02-13 | Rutgers, The State University | Therapeutic azo-compounds for drug delivery |
| EP1315481B1 (de) | 2000-08-29 | 2006-12-06 | Mepha AG | Arzneimittel zur behandlung von darmerkrankungen |
| CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| HU229291B1 (en) * | 2001-01-31 | 2013-10-28 | Evonik Roehm Gmbh | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
| US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
| US7825106B2 (en) * | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
-
2004
- 2004-09-01 US US10/930,743 patent/US7737133B2/en not_active Expired - Lifetime
- 2004-09-02 JP JP2006525214A patent/JP5108304B2/ja not_active Expired - Fee Related
- 2004-09-02 CA CA002535923A patent/CA2535923A1/en not_active Abandoned
- 2004-09-02 EP EP04769427A patent/EP1663253B1/en not_active Expired - Lifetime
- 2004-09-02 DE DE602004030353T patent/DE602004030353D1/de not_active Expired - Lifetime
- 2004-09-02 AT AT04769427T patent/ATE489956T1/de not_active IP Right Cessation
- 2004-09-02 WO PCT/IB2004/003059 patent/WO2005021009A2/en not_active Ceased
- 2004-09-02 ES ES04769427T patent/ES2353761T3/es not_active Expired - Lifetime
- 2004-09-02 MX MXPA06002048A patent/MXPA06002048A/es not_active Application Discontinuation
- 2004-09-02 AU AU2004267953A patent/AU2004267953A1/en not_active Abandoned
-
2006
- 2006-02-13 IL IL173684A patent/IL173684A0/en unknown
- 2006-02-15 ZA ZA200601356A patent/ZA200601356B/en unknown
- 2006-04-03 NO NO20061489A patent/NO20061489L/no not_active Application Discontinuation
-
2010
- 2010-06-10 US US12/797,655 patent/US7928092B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504212A5 (enExample) | ||
| TWI254640B (en) | Use of a polymer of acrylic type as a disintegration agent | |
| RU2485942C2 (ru) | Бупропиона гидробромид и его терапевтические применения | |
| JP2008520736A5 (enExample) | ||
| ES2611483T3 (es) | Agente terapéutico para enfermedad inflamatoria intestinal | |
| JP2011079859A5 (enExample) | ||
| ES2525495T1 (es) | Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| JP2007506774A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| HRP20201352T1 (hr) | Inhibitor fibroze | |
| NZ587897A (en) | Drug delivery systems comprising weakly basic drugs and organic acids | |
| JP2010090168A5 (enExample) | ||
| JP2009526021A5 (enExample) | ||
| US20130267602A1 (en) | Moisture resistant container systems for rapidly bioavailable dosage forms | |
| JP2005528430A5 (enExample) | ||
| TW200831134A (en) | Phenylalkyl carbamate compositions | |
| JP2011506587A5 (enExample) | ||
| JP2009517411A5 (enExample) | ||
| JP2004532828A5 (enExample) | ||
| JP2018039810A5 (enExample) | ||
| RU2018137590A (ru) | Фармацевтические композиции для производного n-пропаргиламина | |
| JP2023506537A (ja) | アゴメラチンを含有する経粘膜治療システム | |
| JP2010506855A5 (enExample) | ||
| JP2004522780A5 (enExample) |